Current medical management of hereditary angioedema

BackgroundPhysician surveys on hereditary angioedema (HAE) management in 2010 and 2013 revealed important trends HAE care.ObjectiveTo evaluate current the impact of new treatment options physician practice patterns over time.MethodsDuring June July 2019, 5382 physicians were contacted by means postal mail to complete a 47-question survey; 177 responded (3%).ResultsAcross 3 surveys, home replaced emergency department as most typically reported setting for attack (54.3% vs 11.6% 32.5% 2013; P < .001). Physicians C1 esterase inhibitor (C1-INH) prescribed long-term prophylactic (LTP) (60.0% 20.4% 56.7% Subcutaneous LTP medications intravenous (C1-INH, 41.4%; subcutaneous lanadelumab, 21%; C1-INH, 18.6%). Danazol, frequently treatment, dropped 6.4% (55.8% 23.4% The strongest nonefficacy factor influencing clinician choice changed time, with cost (or) insurance coverage increasing 43.7% (from 24.4% 40.5% = .001), whereas concern adverse effects 16.2% 55.8% 29.5% Physician-reported patient satisfaction remains high, only 1.5% indicating patients are not satisfied treatment.ConclusionThe US survey data reflect improvements recent years. Therapeutic advances have led higher rates attacks, reduced effects, high levels satisfaction.